American pharmaceutical company Pfizer announced on Friday that its investigational COVID-19 oral antiviral candidate, Paxlovid, showed an 89 per cent reduction in hospitalisation or lethal cases in high-risk patients. ...
Pfizer and BioNTech said on Thursday that a booster shot of their COVID-19 vaccine has shown 95.6 per cent efficacy when compared to those who did not receive the booster dose. ...